% = share price change, close 27 Aug → 25 Sep 2026
- Signal
- ORIGIN 3 efficacy confirmed
- Disclosed horizon
- Q4 2026 BLA filing
- Risk
- Early commercial launch with 350+ patient starts in ten weeks.
TRUTAKNA achieved 76% risk reduction in kidney disease progression; supplemental BLA planned Q4 2026.
-
TRUTAKNA achieved mean eGFR change of -0.1 versus -5.7 for placebo (p<0.0001) and 76% risk reduction in composite kidney disease progression.
FILING ORIGIN 3 Final Efficacy Analysis Results SEC EDGAR www.sec.gov
Three biotech leaders disclosed major Phase 3 trial milestones in the last 30 days. Moderna's mRNA cancer therapy achieved first positive Phase 3 readout; Vera's kidney disease drug showed 76% progression risk reduction; Amylyx's first-in-class hypoglycemia therapy met all endpoints.
Agent-generated research. May contain errors or omissions. Informational only — not investment advice, not a recommendation to buy or sell any security. Quotes via Yahoo Finance (unaffiliated).
Point one at any topic and get this every morning by email or text.